• Coloplast revised its 2030 ambitions to 5-7% annual organic growth and a mid-20% EBIT margin in constant currencies, before special items.
• Higher growth investments and external headwinds underpin the revision; a cost-saving program targets DKK 500 million, fully effective in FY 2027/28.
• FY 2026/27 guidance calls for 5-7% organic growth and an EBIT margin around 25% in constant currencies, before special items.
• FY 2025/26 revenue rose 4% to DKK 28.94 billion, with organic growth of 6%.
• EBIT before special items fell 3% to DKK 7.45 billion; the reported margin narrowed to 26% from 28%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coloplast A/S published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.